durvalumab,tremelimumab
astrazeneca,pfizer
['poseidon']
updated results of poseidon are really interesting. possible interest of tremelumab addition in some specific groups: non-squamous or krasmt (40% alive at 4y !). #esmo2022 
Head of pulmonology unit @pneumo_LS @CHUdeLyon
Professor of Pulmonology @UnivLyon1
Scientific head @URCOT_lyon & @IFCTlung
#liquidbiopsy~#screening~????